Generic Placeholder Website Image

Activity content starts in:

Industry Webcast

Advancing COVID-19 Prevention: The Role of PEP With XOCOVA® (ensitrelvir) Clinical EssentialsIndustry Webcast Sponsored by Shionogi; Not for CME/CE Credit

The period immediately following COVID-19 exposure represents a critical opportunity for intervention. This program will examine the ongoing burden of COVID-19, review the science supporting early antiviral intervention following exposure, and highlight pivotal Phase 3 SCORPIO-PEP data evaluating XOCOVA (ensitrelvir) for PEP. Attendees will gain practical insights into patient identification, treatment considerations, and real-world implementation scenarios to help reduce the risk of symptomatic COVID-19 following exposure.

CME/CE Information

0 Credits - Not for CME/CE Credit

Release Date: 8/19/2026

Expiration Date: 8/19/2026

Faculty

Default Biography Avatar

Jeffrey D. Klausner, MD, MPH

Learn More

Supporters and Partners

Industry Sponsor

Shionogi, Inc.

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

Advancing COVID-19 Prevention: The Role of PEP With XOCOVA® (ensitrelvir) Clinical Essentials

Register